Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lianpu Qingwei granule is a Traditional Chinese Medicine (TCM) botanical formulation developed by the Hubei Provincial Hospital of Traditional Chinese Medicine. It is primarily used for the treatment of gastric disorders associated with stomach heat or damp-heat syndromes, including Helicobacter pylori infection, chronic superficial gastritis, and chronic atrophic gastritis. The formulation is typically composed of multiple herbal extracts, such as Coptis chinensis and Magnolia officinalis, which provide antimicrobial effects against H. pylori and anti-inflammatory protection for the gastric mucosa. In clinical research, it is often evaluated as an adjuvant therapy to standard antibiotic regimens to improve eradication rates and alleviate clinical symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lianpu qingwei granule.